A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients
Nicolas Girard, Daniel Tan, Diego Cortinovis, Gilberto Lopes, Pei Jye Voon, Mesha Austin Taylor, Nadeem Ghali, Lin Zhan, Sheng Xu, Kirsha Naicker, Solange Peters · 2025
Read A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients by Nicolas Girard, Daniel Tan, Diego Cortinovis, Gilberto Lopes, Pei Jye Voon, Mesha Austin Taylor, Nadeem Ghali, Lin Zhan, Sheng Xu, Kirsha Naicker, Solange Peters (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12775713.txt.
Description
Nicolas Girard and co-authors pool trial proof on immune drugs for lung cancer in a 2025 review. Non-small cell lung cancer kills more people than any other cancer, with higher death rates in Asia. Checkpoint drugs work, but whether they work alike in Asian and non-Asian patients was unclear.
The team gathered multiregional randomized trials that split results by Asian subgroup. Drug alone and drug paired with chemotherapy or a second immune agent were weighed across first and later treatment lines. Survival and progression ratios anchor the comparisons. The pooled read aims to guide line-by-line choices for both populations.
Catalog record
| CREATOR | Nicolas Girard, Daniel Tan, Diego Cortinovis, Gilberto Lopes, Pei Jye Voon, Mesha Austin Taylor, Nadeem Ghali, Lin Zhan, Sheng Xu, Kirsha Naicker, Solange Peters |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |